Benlysta Blockbuster BLISS?
Street Thrown for a 'Lupus' as HGS Posts Phase III Win
By Randy Osborne
Tuesday, July 21, 2009
Full rejoicing must wait until November, when the second - and somewhat riskier - lupus trial will report data, but Human Genome Sciences Inc. meanwhile has wowed investors with positive top-line results from a Phase III study with Benlysta (belimumab). (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.